Whole-exome sequencing identified a homozygous BRDT mutation in a patient with acephalic spermatozoa
Metrics: PDF 1408 views | HTML 2903 views | ?
Lin Li1,*, Yanwei Sha2,*, Xi Wang3, Ping Li2, Jing Wang4, Kehkooi Kee1, Binbin Wang3
1Center for Stem Cell Biology and Regenerative Medicine, Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, 100084, China
2Reproductive Medicine Center, Xiamen Maternal and Child Health Care Hospital, Xiamen, 361005, Fujian Province, China
3Center for Genetics, National Research Institute for Family Planning, Haidian, Beijing, 100081, China
4Department of Medical Genetics and Developmental Biology, School of Basic Medical Sciences, Capital Medical University, Beijing, 100069, China
*These authors have contributed equally to this work
Binbin Wang, email: [email protected]
Kehkooi Kee, email: [email protected]
Keywords: acephalic spermatozoa, whole-exome sequencing, BRDT, mutation, RNA-sequencing
Received: July 22, 2016 Accepted: October 19, 2016 Published: February 10, 2017
Acephalic spermatozoa is a very rare disorder of male infertility. Here, in a patient from from a consanguineous family, we have identified, by whole-exome sequencing, a homozygous mutation (c.G2783A, p.G928D) in the BRDT gene. The gene product, BRDT, is a testis-specific protein that is considered an important drug target for male contraception. The G928D mutation is in the P-TEFb binding domain, which mediates the interaction with transcription elongation factor and might affect the transcriptional activities of downstream genes. By RNA-sequencing analysis of cells expressing the BRDT mutation, we found the p.G928D mutation protein causes mis-regulation of 899 genes compared with BRDT wild-type cells. Furthermore, by Gene Ontology analysis, the upregulated genes in p.G928D cells were enriched in the processes of intracellular transport, RNA splicing, cell cycle and DNA metabolic process, revealing the underlying mechanism of the pathology that leads to acephalic spermatozoa.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.